-
2
-
-
0043031147
-
Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract
-
James MW, Hawkey CJ. Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract. Br J Clin Pharmacol 2003;56:146-155
-
(2003)
Br J Clin Pharmacol
, vol.56
, pp. 146-155
-
-
James, M.W.1
Hawkey, C.J.2
-
3
-
-
42449093389
-
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis
-
DOI 10.1161/CIRCULATIONAHA.108.764530, PII 0000301720080422000011
-
Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008;117:2104-2113 (Pubitemid 351572169)
-
(2008)
Circulation
, vol.117
, Issue.16
, pp. 2104-2113
-
-
Solomon, S.D.1
Wittes, J.2
Finn, P.V.3
Fowler, R.4
Viner, J.5
Bertagnolli, M.M.6
Arber, N.7
Levin, B.8
Meinert, C.L.9
Martin, B.10
Pater, J.L.11
Goss, P.E.12
Lance, P.13
Obara, S.14
Chew, E.Y.15
Kim, J.16
Arndt, G.17
Hawk, E.18
-
4
-
-
34249310645
-
Cardiovascular risk, hypertension, and NSAIDs
-
White WB. Cardiovascular risk, hypertension, and NSAIDs. Curr Rheumatol Rep 2007;9:36-43.
-
(2007)
Curr Rheumatol Rep
, vol.9
, pp. 36-43
-
-
White, W.B.1
-
5
-
-
19744380776
-
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
-
DOI 10.1056/NEJMoa050493
-
Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102 (Pubitemid 40365350)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.11
, pp. 1092-1102
-
-
Bresalier, R.S.1
Sandler, R.S.2
Quan, H.3
Bolognese, J.A.4
Oxenius, B.5
Horgan, K.6
Lines, C.7
Riddell, R.8
Morton, D.9
Lanas, A.10
Konstam, M.A.11
Baron, J.A.12
-
6
-
-
34247464709
-
Use of nonsteroidal antiinflammatory drugs: An update for clinicians: a scientific statement from the American Heart Association
-
DOI 10.1161/CIRCULATIONAHA.106.181424
-
Antmann EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634-1642 (Pubitemid 46648649)
-
(2007)
Circulation
, vol.115
, Issue.12
, pp. 1634-1642
-
-
Antman, E.M.1
Bennett, J.S.2
Daugherty, A.3
Furberg, C.4
Roberts, H.5
Taubert, K.A.6
-
7
-
-
13444263619
-
Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study
-
Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-481
-
(2005)
Lancet
, vol.365
, pp. 475-481
-
-
Graham, D.J.1
Campen, D.2
Hui, R.3
-
8
-
-
33847373072
-
Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)
-
ADAPT Research Group
-
Martin BK, Breitner JCS, Evans D; ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006;1:e33.
-
(2006)
PLoS Clin Trials
, vol.1
-
-
Martin, B.K.1
Breitner, J.C.S.2
Evans, D.3
-
9
-
-
55549132996
-
Difluoromethylomithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial
-
Meyskens FL, McLaren CE, Pelot D, et al. Difluoromethylomithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:32-38
-
(2008)
Cancer Prev Res
, vol.1
, pp. 32-38
-
-
Meyskens, F.L.1
McLaren, C.E.2
Pelot, D.3
-
10
-
-
0034702914
-
Cyclooxygenase-1 and 2-dependent prostacyclin formation in patients with atherosclerosis
-
Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and 2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000;102:840-845
-
(2000)
Circulation
, vol.102
, pp. 840-845
-
-
Belton, O.1
Byrne, D.2
Kearney, D.3
Leahy, A.4
Fitzgerald, D.J.5
-
11
-
-
0033524421
-
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
-
DOI 10.1073/pnas.96.1.272
-
McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase-2 (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-277 (Pubitemid 29036089)
-
(1999)
Proceedings of the National Academy of Sciences of the United States of America
, vol.96
, Issue.1
, pp. 272-277
-
-
Mcadam, B.F.1
Catella-Lawson, F.2
Mardini, I.A.3
Kapoor, S.4
Lawson, J.A.5
Fitzgerald, G.A.6
-
12
-
-
0019866090
-
Estimated rate of prostacyclin secretion into the circulation of normal man
-
Fitzgerald GA, Brash AR, Falardeau P, et al. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest 1981;68:1272-1276 (Pubitemid 12235028)
-
(1981)
Journal of Clinical Investigation
, vol.68
, Issue.5
, pp. 1272-1276
-
-
Fitzgerald, G.A.1
Brash, A.R.2
Falardeau, P.3
Oates, J.A.4
-
13
-
-
12844278633
-
Cyclooxygenases, thromboxane, and atherosclerosis: Plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism
-
DOI 10.1161/01.CIR.0000153386.95356.78
-
Egan KM, Wang M, Fries S, et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005;111:334-342 (Pubitemid 40165341)
-
(2005)
Circulation
, vol.111
, Issue.3
, pp. 334-342
-
-
Egan, K.M.1
Wang, M.2
Lucitt, M.B.3
Zukas, A.M.4
Pure, E.5
Lawson, J.A.6
Fitzgerald, G.A.7
-
14
-
-
20544451804
-
Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins
-
Rabausch K, Bretschneider E, Sarbia M, et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res 2005;96:e1-4.
-
(2005)
Circ Res
, vol.96
-
-
Rabausch, K.1
Bretschneider, E.2
Sarbia, M.3
-
15
-
-
67549105888
-
Five year efficacy and safety analysis of the Adenoma Prevention with Celecoxib (APC) trial
-
Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five year efficacy and safety analysis of the Adenoma Prevention with Celecoxib (APC) trial. Cancer Prev Res 2009.
-
(2009)
Cancer Prev Res
-
-
Bertagnolli, M.M.1
Eagle, C.J.2
Zauber, A.G.3
-
16
-
-
33748517838
-
Effect of celecoxib on cardiovascular events and blood pressure in two trials for prevention of colorectal adenomas
-
Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for prevention of colorectal adenomas. Circulation 2006;1028-1035
-
(2006)
Circulation
, pp. 1028-1035
-
-
Solomon, S.D.1
Pfeffer, M.A.2
McMurray, J.J.3
-
17
-
-
68349123550
-
Baseline cardiovascular risk in cancer chemoprevention clinical trials involving NSAIDs: Analysis of cardiovascular toxicity from a randomized placebo-controlled, double-blind trial of difluoromethylomithine plus sulindac for the prevention of sporadic colorectal adenomas
-
Zell JA, Pelot D, Chen W-P, McLaren CE, Gemer EW, Meyskens FL. Baseline cardiovascular risk in cancer chemoprevention clinical trials involving NSAIDs: analysis of cardiovascular toxicity from a randomized placebo-controlled, double-blind trial of difluoromethylomithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res 2009;2:209-212
-
(2009)
Cancer Prev Res
, vol.2
, pp. 209-212
-
-
Zell, J.A.1
Pelot, D.2
Chen, W.-P.3
McLaren, C.E.4
Gemer, E.W.5
Meyskens, F.L.6
|